Is HER2-low a distinct subtype of breast cancer?

Clinical outcomes in women with metastatic HER2-low breast cancer in the real world

DESTINY-Breast04: practice-changing results for HER2-low breast cancer

Remaining questions surrounding HER2-low breast cancer – how low can you go?

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review

Overview of the management of HER2-low breast cancer patients

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancer

The exciting new field of HER2-low breast cancer

New treatment for HER2 low metastatic breast cancer (HB 422)

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancer

Latest news in HER2-low breast cancer

The genomic characterization of primary and metastatic HER2-low breast cancers

Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer

HER2-low expression in breast cancer

The evolution of HER2-low breast cancer from primary to recurrence

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Questions remaining in the field of HER2-low breast cancer

Remaining questions regarding HER2-low breast cancer